Dr. Beau le Roy is a Technical Sales Supervisor at ACROBiosystems, where he contributes to the integration of advanced pharmaceutical solutions with a focus on life sciences. With a PhD in Pharmaceutical Sciences and over a decade of experience in pharmaceutical research, he brings deep technical knowledge and problem-solving expertise to support the DACH team. His postdoctoral work at the University of Zurich refined his skills in drug discovery, and in his current role, he bridges scientific insight with commercial strategy to deliver high-quality, client-focused solutions. Passionate about innovation in healthcare, he is dedicated to translating research into impactful applications.
Autoimmune disease is a collection of multiple severe clinical conditions that affect 3-5% of the total population worldwide, involving disrupted immune cell activation and escalated inflammation in the patients. Amongst other biologics, therapeutic antibodies are a leading and increasingly widely applied approach. With the rapid exploration of new targets and signaling pathways, numerous targets remain to be discovered and optimized. In this talk, we present various case studies, technologies, and analytical methods designed to ensure a ‘native’ protein that is structurally and conformationally accurate, maximizing bioactivity and assisting in the discovery of new targets for autoimmune diseases.